AGO11 Antibody

What is AGO2 and what role does it play in RNA silencing pathways?

AGO2 (Argonaute 2) functions as a key transcriptional regulator through RNA interference and endonucleolytic cleavage. Among Argonaute family proteins, only AGO2 possesses endonucleolytic or "Slicer" activity, enabling it to execute miRNA-directed cleavage of target mRNA when perfect base-pairing exists between the AGO2-associated miRNA and the mRNA sequence. With partial complementarity, AGO2 instead interferes with translation via translational repression activity rather than cleaving the target .

AGO2 serves as a core element of the RISC (RNA-induced silencing complex), initiating target mRNA degradation through its catalytic activity in gene silencing processes guided by siRNAs or miRNAs. It plays a non-redundant role in various small RNA-guided gene silencing processes, including RNA interference, translation repression, and heterochromatinization .

How does AGO2 differ from other Argonaute proteins in structure and function?

The Argonaute family consists of four proteins (AGO1, AGO2, AGO3, and AGO4) that participate in RNA silencing pathways with distinct functional characteristics:

All Argonaute family proteins contain conserved PAZ and PIWI domains critical for small RNA binding and target interaction activities. The unique endonucleolytic activity of AGO2 makes it particularly important for experimental approaches targeting specific RNA silencing .

What applications has the AGO2 11A9 antibody been validated for?

The AGO2 11A9 monoclonal antibody has been validated for several research applications with specific recommended concentrations:

The epitope recognized by AGO2 11A9 detects reduced AGO2 by Western Blot and stains AGO2 in both cytoplasmic and nuclear compartments in Immunocytochemistry. Importantly, the antibody does not cross-react with murine AGO2, which should be considered when designing experiments with mouse models .

What is the optimal sample preparation protocol for detecting AGO2 in different cellular compartments?

For optimal detection of AGO2 in different cellular compartments, researchers should implement a compartment-specific approach:

For cytoplasmic AGO2:

• Use gentle lysis buffers containing non-ionic detergents (0.1-0.5% NP-40 or Triton X-100)

• Maintain samples at 4°C during preparation to preserve protein integrity

• Include protease inhibitors to prevent degradation

For nuclear and chromatin-bound AGO2:

• Employ sequential extraction protocols to separate nucleoplasmic and chromatin-bound fractions

• Begin with low-detergent cytoplasmic extraction, followed by nucleoplasmic extraction

• Use sonication or nuclease treatment for chromatin-bound fractions

• Verify fraction purity using compartment-specific markers (GAPDH for cytoplasm, Lamin B1 for nuclear envelope)

For immunofluorescence applications:

• Compare different fixation methods (4% paraformaldehyde is common)

• Optimize permeabilization conditions (0.1-0.5% Triton X-100)

• For nuclear detection, ensure adequate permeabilization of the nuclear membrane

• Consider confocal microscopy with optical sectioning for accurate nuclear localization assessment

What specificity issues have been identified with the AGO2 11A9 antibody in nuclear studies?

Recent research has revealed significant specificity concerns when using the AGO2 11A9 antibody for studying nuclear functions of AGO2. In a comprehensive study combining Chromatin Immunoprecipitation with high-throughput sequencing (ChIP-seq) and quantitative mass spectrometry (ChIP-MS), researchers initially observed an apparent interaction between AGO2 and the SWI/SNF complex on chromatin, with enrichment at enhancers and transcription start sites .

These findings indicate that:

• The AGO2 11A9 antibody produces misleading results in ChIP, RNA-seq, and mass spectrometry experiments focused on nuclear AGO2

• The antibody directly interacts with the SWI/SNF complex independently of AGO2

• Previously reported associations between AGO2 and chromatin require re-evaluation

This cross-reactivity significantly impacts the interpretation of nuclear localization and function studies using this antibody .

How can researchers validate AGO2 antibody specificity for nuclear function studies?

To validate AGO2 antibody specificity for nuclear function studies, researchers should implement a comprehensive validation strategy:

• Generate AGO2 knockout cell lines: Create CRISPR/Cas9-engineered AGO2^(-/-) cell lines to serve as critical negative controls. Any persistent antibody signal in knockout cells indicates cross-reactivity issues .

• Perform parallel detection with multiple antibodies: Use different AGO2 antibodies targeting distinct epitopes and compare results to identify potential cross-reactivity problems.

• Complementation studies: Rescue AGO2 expression in knockout cells and verify whether the antibody signal is restored in the expected pattern.

• Employ epitope tagging strategies: Express epitope-tagged AGO2 (FLAG, HA, etc.) and compare localization detected by tag antibodies versus AGO2-specific antibodies.

• Conduct ChIP-qPCR validation: Compare ChIP-qPCR results between wild-type and AGO2 knockout cells to determine if chromatin associations are AGO2-dependent or antibody artifacts.

• Perform mass spectrometry validation: Conduct immunoprecipitation with mass spectrometry (IP-MS) in both wild-type and knockout cells to identify non-specific interactions.

• Test for SWI/SNF interaction: Specifically investigate potential cross-reactivity with SWI/SNF components, particularly SMARCC1 .

What are the implications of AGO2 11A9 antibody cross-reactivity with the SWI/SNF complex?

The cross-reactivity of AGO2 11A9 antibody with the SWI/SNF complex has significant implications for research:

This cross-reactivity emphasizes the importance of rigorous antibody validation, particularly when exploring novel cellular localizations or functions of well-studied proteins.

What methodological approaches can distinguish true AGO2 interactions from antibody artifacts?

To distinguish between genuine AGO2 interactions and antibody-mediated artifacts, researchers should implement a multi-faceted validation approach:

• Genetic validation using knockout systems:

  • Generate AGO2 knockout cell lines via CRISPR/Cas9

  • Test antibody binding in knockout cells to identify non-specific signals

  • Perform rescue experiments by re-expressing AGO2 in knockout cells

• Complementary detection strategies:

  • Use orthogonal methods like proximity labeling (BioID, APEX2)

  • Employ epitope-tagged AGO2 with tag-specific antibodies

  • Perform RNA-protein interaction mapping (CLIP-seq)

• Interaction validation:

  • Conduct reciprocal immunoprecipitation targeting suspected interacting partners

  • Analyze stoichiometry of interactions (non-physiological ratios suggest artifacts)

  • Perform competition assays with recombinant AGO2

• Specific controls for SWI/SNF artifacts:

  • Compare binding patterns with known SWI/SNF ChIP-seq datasets

  • Test binding in SMARCC1 knockout or knockdown systems

  • Assess co-localization with established SWI/SNF components

• Functional validation:

  • Demonstrate that disrupting the AGO2 interaction has expected functional consequences

  • Show that AGO2 mutants affect the studied process in predictable ways

  • Correlate interaction data with functional outcomes

These methodological approaches provide a robust framework to distinguish genuine AGO2 biology from technical artifacts.

How do AGO antibodies relate to autoimmune neurological disorders?

Recent research has uncovered a significant relationship between AGO antibodies and autoimmune neurological disorders, particularly sensory neuronopathy (SNN):

• AGO1 antibodies as diagnostic biomarkers: A multicentric case/control study identified anti-AGO1 antibodies in 12.9% (17/132) of patients with SNN, compared to 3.7% (11/301) of patients with non-SNN neuropathies, 5.8% (16/274) of patients with other autoimmune diseases, and 0% (0/116) of healthy controls .

• Disease severity association: AGO1 antibody-positive SNN demonstrated greater severity than AGO1 antibody-negative SNN (SNN score: 12.2 vs. 11.0, p = 0.004) .

• Treatment response prediction: Patients with AGO1 antibody-positive SNN showed significantly better response to immunomodulatory treatments compared to antibody-negative patients (54% vs. 16%, p = 0.02). This difference was particularly pronounced for intravenous immunoglobulin (IVIg) therapy .

• Multivariate analysis confirmation: AGO1 antibody positivity emerged as the only predictor of treatment response in multivariate logistic regression adjusted for potential confounders (OR 4.93, 1.10-22.24 95% CI, p = 0.03) .

• Antibody characteristics:

  • Titers ranged from 1:100 to 1:100,000, with higher titers prevalent in SNN

  • IgG1 was the predominant subclass (88.2% of AGO1 Ab+ SNN patients)

  • 64.7% of AGO1 antibodies bound conformation-specific epitopes

These findings establish AGO1 antibodies as valuable diagnostic and prognostic biomarkers that define a distinct subset of autoimmune sensory neuronopathies with specific clinical characteristics and treatment responsiveness.

What are the conformation-specific binding properties of AGO antibodies?

AGO antibodies demonstrate interesting conformation-specific binding characteristics relevant to both research and clinical applications:

• Prevalence of conformation-specific binding: Among 17 AGO1 antibody-positive patients with sensory neuronopathy (SNN), 11 (64.7%) bound to conformation-specific epitopes rather than linear epitopes .

• Cross-reactivity patterns: Of 16 AGO1 antibody-positive SNN patients tested for AGO2 antibodies, 10 (62.5%) showed positive results, indicating potential cross-reactivity between different AGO proteins or the presence of multiple specificities .

• Titer variation and distribution:

  • ELISA AGO1 antibody titers ranged from 1:100 to 1:100,000 in neuropathy patients

  • Titers ranged from 1:100 to 1:10,000 in patients with other autoimmune diseases

  • Among all patients with the highest titers (≥1:100,000), 80% (4/5) had SNN

• IgG subclass distribution:

The predominance of IgG1 subclass and conformation-specific binding suggests these antibodies recognize AGO proteins in their native conformation, which has implications for both detection methods and understanding pathogenic mechanisms. The high frequency of cross-reactivity between AGO1 and AGO2 also indicates potential epitope sharing between these related proteins .

What advanced experimental controls should be included when studying nuclear AGO2?

When investigating nuclear AGO2, researchers should implement these comprehensive controls to ensure valid results:

• Genetic negative controls:

  • AGO2 knockout cell lines generated using CRISPR/Cas9

  • AGO2 knockdown cells (siRNA or shRNA)

  • Cells expressing AGO2 mutants defective in nuclear localization

• Antibody validation controls:

  • Multiple antibodies targeting different AGO2 epitopes

  • Isotype control antibodies matched to AGO2 11A9

  • Pre-absorption with recombinant AGO2 protein

  • Tests in both native and denatured conditions

• SWI/SNF complex-specific controls:

  • SMARCC1 knockout/knockdown controls to address known cross-reactivity

  • Parallel ChIP experiments for SWI/SNF components

  • Comparison with published SWI/SNF binding datasets

• Cellular fractionation controls:

  • Compartment-specific markers (GAPDH for cytoplasm, Lamin B1 for nuclei)

  • Multiple fractionation protocols to confirm consistency

  • Nuclear integrity verification during preparation

• Functional validation:

  • RNA-dependent vs. RNA-independent interactions

  • Nuclear export inhibition experiments

  • Correlation with functional readouts

These controls are essential to distinguish genuine nuclear AGO2 biology from technical artifacts, especially considering the known cross-reactivity of AGO2 11A9 antibody with SWI/SNF components.

How should researchers interpret ChIP-seq and ChIP-MS data obtained with AGO2 11A9 antibody?

Researchers should apply careful interpretation to ChIP-seq and ChIP-MS data obtained with AGO2 11A9 antibody:

• Critical re-evaluation of enrichment patterns:

  • Cross-reference identified binding sites with known SWI/SNF binding regions

  • Compare with ChIP-seq data for SWI/SNF components, especially SMARCC1

  • Be aware that enrichment at enhancers and transcription start sites may reflect SWI/SNF binding rather than AGO2

• Validation requirements for existing data:

  • Confirm key findings using AGO2 knockout controls

  • Verify with alternative approaches (e.g., CUT&RUN with different antibodies)

  • Perform ChIP-qPCR on selected targets in both wild-type and AGO2 knockout cells

• Protein interaction interpretation guidelines:

  • For ChIP-MS data, evaluate all SWI/SNF components as potential antibody-mediated artifacts

  • Analyze stoichiometry of detected interactions to identify non-physiological associations

  • Confirm genuine interactions with reciprocal immunoprecipitation experiments

• Bioinformatic analysis considerations:

  • Implement computational approaches to distinguish AGO2-specific from SWI/SNF-like binding patterns

  • Consider more stringent peak calling parameters to minimize false positives

  • Compare binding motifs with RNA-binding protein signatures versus chromatin-associated factor motifs

What CRISPR/Cas9 approaches are most effective for validating AGO2 antibody specificity?

CRISPR/Cas9 approaches provide definitive tools for validating AGO2 antibody specificity:

• Complete AGO2 knockout strategy:

  • Design guide RNAs targeting early exons or critical functional domains

  • Generate clonal knockout lines and verify by sequencing

  • Confirm protein loss by Western blot with multiple antibodies

  • Use knockout cells as negative controls in all antibody applications

• Epitope modification approach:

  • Design CRISPR/Cas9 editing to specifically modify the epitope recognized by the antibody

  • Maintain protein function while disrupting antibody binding

  • This directly tests epitope specificity versus non-specific binding

• Endogenous tagging strategy:

  • Use CRISPR/Cas9 to insert small epitope tags (FLAG, HA) at the endogenous AGO2 locus

  • Maintain physiological expression levels and regulation

  • Compare detection between AGO2 antibodies and tag-specific antibodies

  • Creates internal validation within each experiment

• Dual knockout system for cross-reactivity assessment:

  • Generate cell lines with both AGO2 and SMARCC1 knockouts

  • This allows definitive assessment of whether cross-reactivity is specifically with SMARCC1

  • Compare antibody binding patterns in single versus double knockout backgrounds

These CRISPR/Cas9 approaches provide genetic controls essential for distinguishing true signals from artifacts, particularly for nuclear studies where cross-reactivity with SWI/SNF has been documented.

What alternative technologies can researchers use to study AGO2 nuclear functions?

Given the specificity challenges with AGO2 11A9 antibody, researchers should consider these alternative approaches for studying nuclear AGO2:

• Endogenous tagging strategies:

  • CRISPR/Cas9-mediated knock-in of small epitope tags (FLAG, HA)

  • Split-GFP complementation systems for visualization

  • These maintain physiological expression and avoid antibody artifacts

• Proximity labeling approaches:

  • TurboID or miniTurbo fusions to AGO2 for rapid biotin labeling

  • APEX2-AGO2 fusions for proximity-dependent biotinylation

  • These identify neighboring proteins in intact cells without relying on antibodies

• Advanced imaging technologies:

  • Live-cell imaging with fluorescent protein fusions

  • Super-resolution microscopy for precise nuclear localization

  • Single-molecule tracking to follow AGO2 dynamics

  • FRAP (Fluorescence Recovery After Photobleaching) for mobility analysis

• RNA-protein interaction mapping:

  • CLIP-seq techniques optimized for nuclear fractions

  • RNA-MaP for systematic identification of RNA targets

  • RIP-seq with validated epitope tags rather than AGO2 antibodies

• Functional genomics approaches:

  • CRISPRi screens targeting AGO2-regulated genes

  • Mass spectrometry with isotope labeling for quantitative interaction analysis

  • Biochemical fractionation combined with activity assays

These technologies provide orthogonal approaches to study nuclear AGO2 while avoiding the pitfalls associated with antibody cross-reactivity, enabling more reliable characterization of AGO2's nuclear functions.

What are the key considerations for researchers working with AGO2 11A9 antibody?

Researchers working with AGO2 11A9 antibody should consider these essential points:

• Specificity limitations: The AGO2 11A9 antibody exhibits significant cross-reactivity with the SWI/SNF complex, particularly with SMARCC1, independent of AGO2 presence. This cross-reactivity is especially problematic for nuclear studies .

• Validation requirements: All experiments using this antibody should include proper controls, particularly AGO2 knockout cell lines. Previous findings of AGO2 association with chromatin, especially at enhancers and transcription start sites, require re-evaluation .

• Application-specific considerations:

  • Western blot: Use at ≤4 µg/mL and include knockout controls

  • Immunocytochemistry: Use at ≤1.25 µg/mL and validate nuclear staining with alternative methods

  • ChIP applications: Exercise extreme caution; validate with independent approaches

• Alternative approaches: Consider epitope tagging strategies, alternative antibodies, or orthogonal methods like proximity labeling when studying AGO2, particularly for nuclear functions .

• Literature interpretation: Be critical when interpreting published data on nuclear AGO2 functions that rely solely on the 11A9 antibody without proper knockout controls .

The specificity issues with AGO2 11A9 antibody highlight the importance of rigorous validation of research tools, especially when exploring new biological functions of well-studied proteins.

How do findings about AGO antibodies impact both basic research and clinical applications?

The findings about AGO antibodies have significant implications across research and clinical domains: